Allos shares tank after second bid is withdrawn; Rosetta Genomics restructures R&D;

@FierceBiotech: Roche spotlights PhI efficacy of Alzheimer's antibody. Article | Follow @FierceBiotech

@JohnCFierce: Glaxo R&D chief Slaoui outlines his formula for success. News | Follow @JohnCFierce

@RyanMFierce: I saw twitter action on this fertility startup OvaScience a while ago, but @scottkirsner is first to write an article. Report | Follow @RyanMFierce

> Shares of Allos Therapeutics took a dive after the developer announced that a competing buyout bid for the company had been withdrawn. Allos has been working with AMAG on an all-stock transaction which has been heavily criticized by several analysts in the field. The biotech never identified the mystery bidder. Report

> Rosetta Genomics is laying off 35 people in its R&D operations as it moves to cut costs. Story

> Inspiration Biopharmaceuticals named John P. Butler as CEO, replacing Michael Griffith, who has assumed the role of chief scientific officer. Release

> Germany's Agennix has spelled out the data it gathered in a Phase II clinical trial evaluating talactoferrin in patients with previously treated non-small cell lung cancer. The drug hit its primary endpoint and appeared to improve survival across a broad range of patient subgroups. Release

> Roche has recruited Astrazeneca's Dr. Harsukh Parmar to helm translational and experimental medicine for its inflammation discovery and translational area in New Jersey. Item

> U.K. companies in the biosciences field will compete for £18 million of new government funding for new product development. Story

Pharma News

@FiercePharma: Already owing huge amounts to drugmakers, Spain shuts ERs, proposes physician pay cut. Article | Follow @FiercePharma

> FDA adds warning to BMS leukemia drug. Report

> One question on HIV prevention: Will patients take their meds? More

> Dekkers uses tennis lessons at Bayer's helm. Story

> India won't cap foreign M&A, but deals will face review. News

> Europe aims to tighten up pharma info channels. More

> Jury adds $162M to damages in Teva case. Item

Manufacturing News

> Counterfeits quantified. Story

> AZ ups emerging markets bet with $200M plant in China. Report

> Sanofi's Viehbacher sees green lights ahead for Shantha. Article

> Kimberly-Clark program gives new life to cleanroom garb. Report

> Sen. Schumer asks FTC to probe gray market mark-ups in drug shortages. Story

> Teva, partners fined $20M in second propofol/Hep-C case. News

Biotech Research News

> Great minds collaborate on new RNAi approach to inflammation. Story

> Cloning tech used to create breakthrough stem cells for research. Article

> Diabetes science team finds a "negative regulator" for insulin secretion. Report

> Natural compound shows promise as a pathway to diabetes pill. Item

And Finally... It turns out that chocolate offers some extraordinary health benefits. Story

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.